Kukje Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kukje Pharma makes prescription and over-the-counter medicines, including eye drops, soft-gel capsules, and oral tablets, used by patients across South Korea.
It supplies pharmacies, clinics, hospitals, and wholesale distributors through a nationwide sales force. Listed on KOSPI, Korea's main stock exchange, the company operates its own manufacturing and research facilities in Ansan, Gyeonggi Province, and is currently running several active drug-development programmes, including research into new drugs and improved formulations of existing ones.
Summary is AI-generated and may contain errors · figures from DART filings
The company maintains its own in-house manufacturing and research site in Ansan, giving it integrated production and development capabilities under one roof.
Kukje Pharma in five facts
What does Kukje Pharma do?
Kukje Pharma makes prescription and over-the-counter medicines, including eye drops, soft-gel capsules, and oral tablets, used by patients across South Korea.
Where is Kukje Pharma listed and in which sector?
Kukje Pharma (Korean name: 국제약품) trades under KRX code 002720 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kukje Pharma?
Its market capitalisation was US$61.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kukje Pharma's latest annual revenue and operating profit?
For fiscal year 2025, Kukje Pharma reported revenue of US$132.5M, operating profit of US$4.7M and net income of US$4.3M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 12.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on large shareholdings (5% rule) (standard)Oct 7
- Change of largest shareholderOwnership change · Oct 6
- Change in shares held by the largest shareholderOct 6
- Change in shares held by the largest shareholderSep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- Executives/major shareholders' securities trading planSep 4
- Executives/major shareholders' securities trading planSep 4
- Cash/in-kind dividend decision
Kukje Pharma declared a cash dividend of US$0.02 per share.
Dividend · Feb 25